The Quantum Sensor That Gives Cancer Nowhere to Hide

ULM, GERMANY – June 16, 2026 – For any patient undergoing cancer treatment, the most agonizing question is also the simplest: Is it working? For decades, the answer has been trapped in a frustrating time warp. While powerful therapies attack disease at the cellular level, our tools for measuring their success have remained stubbornly focused on macro changes. We wait for months to see if a tumor shrinks, a period filled with uncertainty and the physical toll of treatments that may be ineffective. This week, the industrial and healthcare worlds took note of a German company that promises to end this agonizing wait.

NVision Quantum Technologies, a quantum technology firm based in Ulm, was just named a winner of Fast Company’s 2026 World Changing Ideas Award. The accolade recognizes POLARIS, its quantum-enhanced MRI platform, a system that doesn't just see disease, but sees how it behaves in real time. It’s a foundational shift from static anatomical snapshots to dynamic metabolic movies, and it represents a critical transition for quantum technology—from the esoteric realm of theory to the front lines of healthcare.

The Agonizing Wait: A Blind Spot in Modern Oncology

Magnetic Resonance Imaging (MRI) is a cornerstone of modern diagnostics, providing incredibly detailed images of a tumor's size and location. It tells doctors where the enemy is. What it cannot easily tell them is how the enemy is reacting to an attack. The metabolic processes that signal a cancer cell’s death or continued proliferation happen long before the tumor itself shrinks or grows. This creates a diagnostic blind spot lasting weeks or even months.

For patients, this delay means enduring the grueling side effects of chemotherapy or immunotherapy without knowing if it's providing any benefit. For clinicians, it means making critical decisions with incomplete data. In a world of precision medicine, we are still waiting for crude, lagging indicators. The cost is measured in wasted time, unnecessary toxicity, and diminished hope. It’s this fundamental challenge that NVision’s award-winning technology was built to solve.

Making Metabolism Visible: The POLARIS Breakthrough

POLARIS transforms a standard MRI machine from a structural camera into a metabolic observatory. The platform addresses the visibility gap by producing a special imaging agent on-site and then using quantum physics to “turn up the volume” on its signal, making the inner workings of cellular metabolism visible during a routine scan.

The core innovation is a process called Parahydrogen-Induced Polarization (PHIP). In simplified terms, NVision engineers the quantum properties of organic molecules, transferring a highly ordered quantum state from parahydrogen gas to a metabolic tracer like pyruvate. This process, which takes mere seconds, hyperpolarizes the tracer, boosting its MRI signal by a factor of more than 10,000. When this supercharged agent is introduced into the body, its journey through metabolic pathways can be tracked in real time. For the first time on a scalable platform, researchers and clinicians can watch how a tumor is consuming energy, offering an almost immediate clue as to whether a therapy is working.

“With POLARIS, our goal is to make metabolism visible through MRI and help researchers better understand disease biology and treatment response in living systems,” said Sella Brosh, CEO and co-founder of NVision, in the company's announcement. The system’s design is a masterclass in practical innovation: it’s a self-contained unit that connects to existing MRI infrastructure, producing the imaging agent on-demand without the need for cryogenic facilities or specialized quantum expertise on-site.

From Disruptive Idea to Deployed Reality

The Fast Company award is not just for a clever concept; it recognizes a tangible solution that is already gaining significant traction. This accolade follows a period of immense momentum for NVision, underscored by a recent $55 million Series B financing round. The round was notably anchored by Abbott, a global diagnostics leader, signaling a powerful vote of confidence from the established medical industry. This brings NVision’s total funding to $120 million, with backing from the European Investment Bank and venture firms like Playground Global.

This capital is fueling an aggressive global scale-up. POLARIS systems are already deployed at world-renowned research institutions, including Memorial Sloan Kettering Cancer Center (MSK) in the U.S., the University of Cambridge in the U.K., and the Technical University of Munich in Germany. At MSK, researchers are using the platform in preclinical studies on pancreatic, prostate, breast, and brain tumors. NVision expects to have approximately 20 systems deployed across the U.S., Europe, and Asia by the end of 2026, with multi-center clinical studies slated to begin in 2027.

The Next Quantum Frontier: Computing and Validation

While revolutionizing medical imaging is a world-changing idea in itself, NVision’s ambition extends even further. The deep expertise the company developed in controlling the quantum states of molecules has unlocked a second, equally disruptive path: quantum computing.

NVision is now leveraging its discoveries to build a new type of quantum computer based on Photonic Integrated Quantum Circuits (PIQC). This platform uses the same class of specially engineered organic molecules as qubits—the fundamental building blocks of a quantum computer. By integrating these qubits directly onto photonic chips, NVision is pursuing an approach that is compatible with standard semiconductor manufacturing, a strategy that could offer a more direct path to building fault-tolerant, large-scale quantum computers.

This creates a powerful, unified vision for the future of drug development. In this future, NVision’s quantum computers could design novel drug candidates to tackle intractable diseases, while its POLARIS quantum sensors would be used to rapidly validate their effectiveness in living biological systems. This “compute and validate” loop could dramatically accelerate the pharmaceutical R&D cycle, closing the gap between a promising molecular design and a proven, life-saving therapy.

NVision’s journey demonstrates that the quantum revolution is not a distant, abstract event. It is happening now, in practical systems designed to solve our most urgent challenges. As Fast Company editor-in-chief Brendan Vaughan noted, the awards celebrate tangible solutions that address global challenges with “creativity and rigor.” In the fight against cancer, seeing the enemy’s next move isn't just an advantage; it’s a lifeline, and NVision is delivering the technology that finally lets us watch.